DNA Nanostructure-Based Electrochemical Assay for Sensitive and Quantitative Detection of Diverse Analytes

This technology uses engineered DNA nanostructures with multiple signal tags on electrodes to detect small molecules and proteins. Binding of a target changes the electrical signal, enabling highly sensitive, rapid point-of-care diagnostic tests.

Background

The field of point-of-care diagnostics has seen significant advancements in recent years, driven by the need for rapid, sensitive, and portable detection of small molecules, peptides, and biologics outside of centralized laboratory settings. Traditional diagnostic methods often require bulky instrumentation, lengthy processing times, and skilled personnel, limiting their accessibility and practicality in decentralized environments such as clinics, remote locations, or at-home testing. DNA-based electrochemical assays have emerged as a promising alternative due to their inherent stability, specificity, and compatibility with miniaturized platforms. These assays offer the potential for real-time, quantitative measurements directly at the site of care, addressing the growing demand for timely and actionable diagnostic information in both clinical and consumer health contexts.

Despite these advantages, current DNA-based electrochemical assays face significant limitations that hinder their widespread adoption and effectiveness. One of the primary challenges is their relatively low signal output, which restricts sensitivity and makes it difficult to detect low-abundance analytes without complex amplification steps. Traditional designs often rely on single redox-active tags and short spacer segments, resulting in weak electrochemical signals and limited dynamic range. Efforts to improve sensitivity have typically involved cumbersome signal amplification techniques or increased probe densities, which can introduce variability, increase costs, and complicate assay protocols. Furthermore, the use of short spacers can limit the degree of signal suppression upon target binding, reducing the assay’s ability to discriminate between bound and unbound states. These shortcomings highlight the need for new approaches that can deliver higher sensitivity, stronger signals, and more robust performance in practical, point-of-care diagnostic applications.

Technology

This technology is a DNA nanostructure-based electrochemical assay designed for highly sensitive detection of small molecules, biologics, and peptides, particularly in point-of-care diagnostic applications. The core structure consists of a continuous DNA molecule featuring two hairpin motifs, an anchor recognition moiety specific to the target analyte, and a signal moiety incorporating multiple redox-active tags—typically 3 to 8 methylene blue molecules. This nanostructure is immobilized onto a conductive substrate, such as a gold electrode, using a thiol-DNA spacer segment optimized to be 8–20 adenine nucleotides in length. When the target analyte binds to the recognition moiety, the interaction alters the diffusion dynamics of the signal moiety relative to the electrode, resulting in a measurable change in the electrochemical signal. This signal change is quantified using techniques like square wave voltammetry, allowing for precise determination of analyte concentration.

What differentiates this technology is its innovative combination of multiple redox tags and an optimized, longer DNA spacer, which together yield a dramatic amplification of the electrochemical signal and enhanced sensitivity compared to previous DNA-based assays. While earlier approaches favored shorter spacers and single redox tags, this solution demonstrates that longer spacers (8–20 adenines) paired with multiple methylene blue tags not only increase the baseline signal by up to 60-fold but also maximize signal suppression upon target binding—enabling detection of analytes at extremely low concentrations. The modular design allows for easy customization of the recognition moiety to detect a wide variety of targets, making the platform broadly adaptable for diverse diagnostic needs. Its compatibility with miniaturized, automated systems further positions it as an ideal solution for rapid, accurate point-of-care testing, overcoming the limitations of traditional, centralized laboratory diagnostics.

Benefits

  • Significantly enhanced electrochemical signal sensitivity through multiple redox tags (3–8 methylene blue molecules) on a single DNA nanostructure.
  • Optimized thiol-DNA spacer length (8–20 adenine nucleotides) improves signal suppression and detection sensitivity upon target binding.
  • Highly customizable anchor recognition moiety enables detection of diverse analytes including small molecules, peptides, proteins, and biomarkers.
  • Robust and stable assay design suitable for miniaturization and integration into point-of-care diagnostic platforms.
  • Rapid and quantitative analyte detection with signal changes proportional to target concentration, supporting low detection limits (down to ~1 pM).
  • Adjustable probe density allows tuning of assay sensitivity and dynamic range for various diagnostic needs.
  • Manufacturable and scalable system compatible with standard conductive substrates like gold electrodes.

Applications

  • Point-of-care disease diagnostics
  • Therapeutic drug monitoring
  • Biomarker detection in clinical samples
  • Rapid infectious disease screening
  • Environmental toxin monitoring

Additional info

A DNA nanostructure-based electrochemical assay features a continuous DNA molecule with two hairpin motifs, an analyte recognition moiety, and 3-8 redox-active molecules. Immobilized on an electrode via an 8-20 adenine nucleotide spacer, target binding alters signal moiety diffusion, causing a measurable electrochemical change. Multiple redox tags and the optimized spacer length significantly amplify detection sensitivity.